您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > G5-7
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
G5-7
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
G5-7图片
规格:98%
分子量:383.39
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍
G5-7 是具有口服活性的 JAK2 变构抑制剂,可通过结合到 JAK2,选择性的抑制 JAK2 介导的 EGFR 和 STAT3 的磷酸化和激活。G5-7 诱导细胞周阻滞和诱导凋亡、具有抗血管生成活性。G5-7 有用于胶质瘤研究的潜能。
货号:ajcx33342
CAS:939681-36-4
分子式:C22H19F2NO3
分子量:383.39
溶解度:DMSO : 83.33 mg/mL (217.35 mM; Need ultrasonic)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

G5-7, an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study[1].

G5-7 (0-5 μM) inhibits EGFR tyrosine phosphorylation and downstream mTOR signaling and arrests the cell cycle at G2 phase[1].G5-7 does not directly inhibit EGFR activation[1].G5-7 (0-10 μM) comparably increases the abundance of markers (cleved-PARP and caspase 3) of apoptosis in parental LN229 cells and U87MG/EGFRvIII cells[1].G5-7 interacts with full-length JAK2[1].G5-7 significantly inhibits EGFR Tyr1068 phosphorylation but had no effect on EGFR Tyr1045 phosphorylation[1].G5-7 downregulates the downstream signaling of JAK by mTOR[1].

G5-7 (10 and 50 mg/kg, oral gavege) decreases VEGF secretion and exerts a potent antiangiogenic effect[1].

[1]. Kunyan He, et al. Blockade of glioma proliferation through allosteric inhibition of JAK2. Sci Signal. 2013 Jul 9;6(283):ra55.